The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis

BACKGROUND: The optimal duration of anticoagulation in patients with active cancer and venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate anticoagulant therapy for 3–6 months and to continue anticoagulant therapy for as long as the cancer is active. However, an adequate sy...

Descripción completa

Detalles Bibliográficos
Autores principales: van Hylckama Vlieg, Marte A.M., Nasserinejad, Kazem, Visser, Chantal, Bramer, Wichor M., Ashrani, Aneel A., Bosson, Jean-Luc, Crusan, Daniel J., D'Alessio, Andrea, Fluharty, Meg E., Ģībietis, Valdis, Hansson, Per-Olof, Hara, Nobuhiro, Jara-Palomares, Luis, Kraaijpoel, Noémie, Mahé, Isabelle, Marshall, Andrea, Ogino, Yutaka, Otero, Remedios, Versmissen, Jorie, Klok, Frederikus A., Kruip, Marieke J.H.A., van der Rijt, Carin C.D., Geijteman, Eric C.T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507196/
https://www.ncbi.nlm.nih.gov/pubmed/37731937
http://dx.doi.org/10.1016/j.eclinm.2023.102194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507196/
https://www.ncbi.nlm.nih.gov/pubmed/37731937
http://dx.doi.org/10.1016/j.eclinm.2023.102194

Ejemplares similares